CRSP stock forecast
Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$.
In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. During that period the price should oscillate between -7.90% and +8.10%.
In the medium term (3months), CRSP's stock price should underperform the market by -0.73%. During that period the price should oscillate between -16.76% and +21.47%.Get email alerts
Create a solid portfolio with CRSP
About CRISPR Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
At the moment the company generates 289M USD in revenues.
On its last earning announcement, the company reported a profit of 0.95$ per share.
The book value per share is 5.62$
Three months stock forecastDec. 4, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|